Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study-Reference-Cited by-同舟云学术

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study

Published:2019-10 Issue:10 Volume:20 Page:1386-1394
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ornstein Moshe C,Pal Sumanta K,Wood Laura S,Tomer Jackie M,Hobbs Brian P,Jia Xuefei S,Allman Kimberly D,Martin Allison,Olencki Thomas,Davis Nancy B,Gilligan Timothy D,Mortazavi Amir,Rathmell W Kimryn,Garcia Jorge A,Rini Brian I

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

2. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

3. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma;Albiges;Eur J Cancer,2015

4. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma;Nadal;Ann Oncol,2016

5. Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitors (ICI);Shah;Proc Am Soc Clin Oncol,2018

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab;Clinical Genitourinary Cancer;2024-12

2. Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations;Kidney Cancer;2024-09-05

3. Real-World Outcomes in Patients with Advanced/Metastatic Renal Cell Carcinoma Receiving Cabozantinib or Other Tyrosine Kinase Inhibitors After Checkpoint Inhibitor-Based Therapy;Kidney Cancer;2024-08-02

4. Renal cell carcinoma;The Lancet;2024-08

5. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2024-08